A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
Recruiting · NCT07185880 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-04-14 | NCT07185880 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
| Myosin Therapeutics Inc. | 2 |
| National Cancer Institute (NCI) | 3015 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic Hospital | Rochester | United States | 3 |
| Mayo Clinic Hospital | Jacksonville | United States | 6 |
| Mayo Clinic Hospital | Phoenix | United States | 41 |